October 1, 2019

  
Boehringer Ingelheim obtains EMA authorisation for new porcine parvovirus vaccine
 

After obtaining the marketing authorisation from the European Commission, Boehringer Ingelheim launches Reprocyc^® ParvoFLEX in selected countries within the EU, a new porcine parvovirus vaccine to protect swine foetuses against transplacental infection caused by porcine parvovirus (PPV).
 

PPV is a reproductive disease present in most swine farms worldwide. It causes foetal death, particularly mummification of foetuses, and is associated with other reproductive disorders. Many vaccines against PPV are available in the market; however, Reprocyc ParvoFLEX is the first subunit vaccine based on a more recent isolate from 2001 (strain 27a) that uses a manufacturing technology of baculovirus expression system (also used with Ingelvac CircoFLEX^®) to express one region of the virus (VP2 region) where most of the immune response is targeted.
 

Reprocyc ParvoFLEX can be mixed and administered with Reprocyc PRRS EU, a vaccine for active immunisation of breeding females affected with European (genotype 1) Porcine Reproductive and Respiratory Syndrome (PRRS); it is approved for use at any stage of gestation and lactation, and so can be introduced to the current PRRS control programmes of sow herds.
 

PRRS continues to be a highly prevalent disease in swine farms causing economic losses through its negative effects on reproduction and growth as well as by clinical illness.
 

Martin Forchieri, marketing head of Swine Strategic Business Unit at Boehringer Ingelheim, shared, "I am really proud we continuously bring innovation to the market and keep addressing our customers' needs." This sentiment was echoed by Xavier de Paz Solanes, global brand manager at Boehringer Ingelheim, who added, "With this new product, veterinarians and producers can simultaneously control two of the most prevalent reproductive diseases in swine herds."